Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.30 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS2 | P35228 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1195455 | 0.84 | — | — | |
| SCHEMBL21236897 | 0.72 | NOS3 (0.37) | HRH3NOS3NOS1NOS2 | |
| SCHEMBL771897 | 0.72 | — | — | |
| SCHEMBL1710042 | 0.72 | KDM4E (0.37) | HRH3NOS3NOS1NOS2 | |
| SCHEMBL19932127 | 0.72 | NOS3 (0.37) | HRH3NOS3NOS1NOS2 | |
| SCHEMBL23772 | 0.71 | — | — | |
| SCHEMBL16268871 | 0.71 | — | — | |
| SCHEMBL21273972 | 0.70 | — | — | |
| SCHEMBL738247 | 0.70 | HRH3 (0.33) | HRH3 | |
| SCHEMBL772354 | 0.70 | HTR1A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | claimed |
| EP-4219495-A1 | AHR MODULATORS | Ideaya Biosciences, Inc. (US) | 2023-08-02 | — | — | EP | claimed |
| US-20230138795-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL PORTELA & CA SA (PT) | 2023-05-04 | — | — | US | claimed |
| EP-3749669-B1 | AHR MODULATORS | IDEAYA BIOSCIENCES INC (US) | 2023-03-08 | — | — | EP | claimed |
| EP-3298011-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-11-17 | — | — | EP | claimed |
| US-20210171528-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2021-06-10 | — | — | US | claimed |
| EP-3749669-A1 | AHR MODULATORS | Ideaya Biosciences, Inc. (US) | 2020-12-16 | — | — | EP | claimed |
| EP-3720856-A1 | DOPAMINE-& X392;-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2020-10-14 | — | — | EP | claimed |
| CN-111479812-A | dopamine-B-hydroxylase inhibitors | 巴尔-波特拉及康邦亚股份有限公司 | 2020-07-31 | — | — | CN | claimed |
| WO-2019156987-A1 | AhR MODULATORS | IDEAYA BIOSCIENCES, INC. (US) | 2019-08-15 | — | — | WO | claimed |
| WO-2016087370-A1 | CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-06-09 | — | — | WO | claimed |
| US-20160107997-A1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-04-21 | — | — | US | claimed |
| EP-3004082-A1 | CXCR7 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2016-04-13 | — | — | EP | claimed |
| WO-2014191929-A1 | CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-04 | — | — | WO | claimed |
| US-20090325954-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-31 | — | — | US | claimed |
| CN-101535296-A | 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | CN | claimed |
| EP-2061784-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-05-27 | — | — | EP | claimed |
| WO-2008032027-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| WO-2008032086-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| WO-2008032077-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107997-A1 | CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, CXCR2 | HRH3 246/4885NOS3 2622/4885NOS1 1884/4885 |
| US-20090325954-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | PIK3CA, MTOR, PIK3CD | HRH3 1741/4885NOS3 2301/4885NOS1 2179/4885 |
| US-20230138795-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, COMT | HRH3 68/4885NOS3 1093/4885NOS1 918/4885 |
| US-20210171528-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, COMT | HRH3 73/4885NOS3 1033/4885NOS1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.